×
News
March 14, 2018

CJEU rules that a Concerned Member State cannot determine the regulatory data protection period of a reference medicinal product

BioSlice Blog
By Libby Amos Jacqueline Mulryne
Find more content tagged:

Stay up-to-date with the latest topics from the firm.

Email Subscriptions RSS Feed (All Perspectives) RSS Feed (News Only)

People

Libby Amos
Libby Amos
Associate
London
+44 (0)20 7786 6193
libby.amos@arnoldporter.com
VCard
Jacqueline Mulryne
Jacqueline Mulryne
Partner
London
+44 (0)20 7786 6123
jacqueline.mulryne@arnoldporter.com
VCard

Related Articles

March 27, 2020
Latest Guidance of the EMA and European and UK National Authorities on Crisis Management of Clinical Trials and Medicine Supplies During the COVID-19 Pandemic
Coronavirus: Life Sciences and Healthcare Regulatory Advisory
March 27, 2020
Two months to go: Latest on the implementation of EU MDR (Part 2)
BioSlice Blog
March 26, 2020
STOP PRESS! Possible delay to the EU MDR
BioSlice Blog

Email Disclaimer

Reject Accept